[Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review]

Area of Science:

• Genetics
• Molecular Biology
• Hematology

Background:

• High-throughput sequencing has identified numerous genetic abnormalities in myelodysplastic syndromes (MDS).
• The functional significance of these mutations in MDS development remains incompletely understood.
• Mutations in splicing factors are the most frequent genetic alterations observed in MDS.

Purpose of the Study:

• To review the role of aberrant splicing in the pathogenesis of myelodysplastic syndromes.
• To highlight the impact of mutations in splicing factors on mRNA splicing and hematopoietic function.
• To discuss the potential of targeting the mis-splicing pathway for MDS therapeutics.

Main Methods:

• Literature review of studies investigating genetic mutations in MDS.
• Analysis of recent findings on splicing factor mutations (SF3B1, SRSF2, U2AF1) and their functional consequences.
• Synthesis of information on aberrant mRNA splicing and its link to hematopoietic dysfunction.

Main Results:

• Mutations in splicing factors like SF3B1, SRSF2, and U2AF1 are prevalent in MDS.
• These mutations lead to aberrant mRNA splicing, causing hematopoietic dysfunction.
• Aberrant splicing is a key driver in the pathogenesis of MDS.

Conclusions:

• Aberrant mRNA splicing, driven by mutations in splicing factors, plays a critical role in MDS pathogenesis.
• Understanding these splicing defects provides insights into MDS development.
• The mis-splicing pathway presents a promising avenue for the development of novel therapeutic targets in MDS.